Treating RRFL in the Community: How Patient Profiles and Disease Trajectory Shape Treatment Decisions

In this episode titled, 'Treating RRFL in the Community: How Patient Profiles and Disease Trajectory Shape Treatment Decisions,' Tara Graff, DO, MS led the conversation about the following questions:

Community oncology practices manage the vast majority of follicular lymphoma patients in the United States. How would you characterize the relapsed or refractory follicular lymphoma (RRFL) patient population in your practice, and how does treating these patients in the community differ from what you see described in academic trial settings?

What factors most commonly drive treatment decisions at first and subsequent relapse in a community practice context?

Tara Graff noted that while RRFL patients themselves do not look fundamentally different between community and academic settings, what varies is how those patients are managed at relapse, with disease trajectory serving as one of the most critical and sometimes underappreciated factors in community practice treatment decision-making. She highlighted the POD24 population as a group that warrants particular attention in the community setting, where this high-risk designation does not always receive the same level of clinical scrutiny it receives in academic and trial contexts, emphasizing that patients who relapse quickly from frontline therapy require a more aggressive second-line approach rather than defaulting to monotherapy. Tara Graff also outlined the full range of patient-specific factors that should inform treatment selection at relapse, including age, comorbidities, quality of life goals, and practical lifestyle considerations, noting that understanding a patient not just medically but as a whole person is essential to selecting a therapy that is both clinically appropriate and sustainable for that individual's life circumstances.

Throughout the conversation, the experts provide a comprehensive reflection on the field and the factors that may shape how clinicians approach care moving forward.

In the next episode, 'Translating PFS Data for Patients: How Community Oncologists Communicate Trial Outcomes in RRFL,' Tara Graff will continue her discussion on follicular lymphoma and highlight how she translates progression-free survival data into meaningful, accessible information for patients.